Prosecution Insights
Last updated: April 19, 2026

4TEEN4 Pharmaceuticals GmbH

3 pending office actions

Portfolio Summary

3
Total Pending OAs
1
Final Rejections
2
Non-Final OAs

Pending Office Actions

App #TitleExaminerArt UnitStatusFiled
17984611 DPP3 BINDER DIRECTED TO AND BINDING TO SPECIFIC DPP3-EPITOPES AND ITS USE IN THE PREVENTION OR TREATMENT OF DISEASES/ACUTE CONDITIONS THAT ARE ASSOCIATED WITH OXIDATIVE STRESS WEN, SHARON X 1641 Non-Final OA Nov 10, 2022
17802799 DPP3 FOR THERAPY GUIDANCE, MONITORING AND STRATIFICATION OF NT-ADM ANTIBODIES IN PATIENTS WITH SHOCK AEDER, SEAN E 1642 Final Rejection Aug 26, 2022
17416197 THERAPY GUIDANCE AND/OR THERAPY MONITORING FOR A TREATMENT WITH ANGIOTENSIN-RECEPTOR-AGONIST AND/OR A PRECURSOR THEREOF RAMADAN, OMAR 1678 Non-Final OA Jun 18, 2021

Managing 4TEEN4 Pharmaceuticals GmbH's Patent Portfolio?

IP Author helps IP teams respond to office actions faster with AI-generated responses, examiner analytics, and prosecution intelligence.

Start Free Trial

Sign in with your work email

Enter your email to receive a magic link. No password needed.

Personal email addresses (Gmail, Yahoo, etc.) are not accepted.

Free tier: 3 strategy analyses per month